Ligand Pharmaceuticals LGND Payments to Acquire Other Investments
Payments to Acquire Other Investments at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireOtherInvestments.
The official record: Ligand Pharmaceuticals’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's payments to acquire other investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's payments to acquire other investments?
- Ligand Pharmaceuticals (LGND) reported payments to acquire other investments of $961.75K in Q4 2025.
- How has Ligand Pharmaceuticals's payments to acquire other investments changed year-over-year?
- Ligand Pharmaceuticals's payments to acquire other investments increased by 53.9% year-over-year, from $625K to $961.75K.